TGen Celebrates 20 Years of Impact

20 years ago, TGen, the Translational Genomics Research Institute was a vision our community embraced. Today, TGen is an Arizona-based, nonprofit medical research institute dedicated to conducting groundbreaking research with life-changing results. TGen works to unravel the genetic components of common and complex diseases, including cancer, neurological disorders, infectious disease, and rare childhood disorders. By identifying treatment options in this manner, TGen believes medicine becomes more rational, more precise and, well, more personal.Continue reading

Aqualung Therapeutics Extends Global Reach With LeaderMed License Agreement

TUCSON, AZ / ACCESSWIRE / April 20, 2022 / Aqualung Therapeutics, an early stage immunotherapeutics biotech company developing an anti-inflammatory therapeutic platform for serious unchecked inflammatory disorders, announced the signing of a license agreement with the LeaderMed Health Group Limited (“LeaderMed”). The License Agreement provides LeaderMed with Asia-Pacific regional rights to further develop, manufacture, and commercialize the eNAMPT-neutralizing mAb, ALT-100 platform technology. The terms of the agreement have not been publicly disclosed but involve customary upfront fees, achievement milestones, and royalties that coincide with commercial sales.Continue reading